Independent
Tenure on this board
1.0 yrs
Also a director at
Seaport Therapeutics Inc (SPTX)
Meeting calendar
BNTC · Annual meeting · Thursday, December 3, 2026
Benitec Biopharma Inc
3 nominees · 3 ballot items.
Stockholders will vote on the election of three Class I directors, ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal 2027, and a non-binding advisory vote approving named executive officer compensation.
Market cap
$315M
1Y TSR
-39.3%
Board grade
C
Record date
Oct 13, 2026
Filing
DEF 14A
Filed Oct 20, 2026 · DEF 14A
Proposals
On the ballot3
- 1
Election of Class I Directors
ManagementBoard: FORElect Dr. Sharon Mates, Kishen Mehta, and Edward Smith as Class I directors to serve until the 2029 Annual Meeting or until their successors are elected and qualified.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the Audit Committee’s appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027.
- 3
Advisory Vote on Executive Compensation
ManagementBoard: FORApprove, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the proxy statement, including the compensation tables and narrative discussion.
More detail
Proposal 3 asks stockholders to approve, on a non-binding advisory basis, the compensation paid to Benitec’s named executive officers as disclosed in the proxy statement. The resolution covers the compensation tables and related narrative disclosure rather than a specific compensation component or individual award. The vote is required under Section 14A of the Securities Exchange Act and is part of the Company’s annual say-on-pay process, which stockholders approved to hold annually at the 2021 annual meeting. Management argues that the program is intended to attract, reward, and retain executives needed to support continued growth and success. The program combines base salary, discretionary cash bonuses, and equity awards, with equity intended to align executives with long-term stockholder interests. Fiscal 2026 compensation included substantial stock-option awards for the CEO, CFO, and COO, making equity valuation a significant component of reported pay. The Compensation Committee periodically reviews the program for competitiveness, alignment with stockholder interests, and consistency with market practices. The advisory vote does not bind the Company, Board, or Compensation Committee, but those bodies state that they will consider the outcome in future compensation decisions. The Board recommends a vote FOR because it believes the disclosed program is competitive and aligned with long-term stockholder interests.
Director elections
Nominees on the ballot3
Kishen Mehta
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
6.5 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | MONTANOVA CAPITAL, LLC | 33.1% | 11,548,351 | $155M |
| 2 | Jupiter Topco LLC | 7.1% | 2,478,547 | $33M |
| 3 | FRANKLIN RESOURCES INC | 6.9% | 2,412,888 | $32M |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.1% | 2,120,672 | $28M |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 5.3% | 1,850,000 | $25M |
| 6 | Nantahala Capital Management, LLC | 4.3% | 1,488,371 | $20M |
| 7 | Simplify Asset Management Inc. | 2.9% | 1,005,557 | $13M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 2.7% | 954,533 | $13M |
| 9 | INFINITUM ASSET MANAGEMENT, LLC | 2.6% | 923,006 | $12M |
| 10 | MILLENNIUM MANAGEMENT LLC | 2.6% | 921,299 | $12M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Benitec Biopharma Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Turn Therapeutics IncTTRX
Annual meeting·Nov 30, 2026·$312M
Galectin Therapeutics IncGALT
Annual meeting·Dec 3, 2026·$346M
Tilray Brands IncTLRY
Annual meeting·Nov 18, 2026·$448M
Angiodynamics IncANGO
Annual meeting·Nov 17, 2026·$497M
Entera Bio LtdENTX
Special meeting·Nov 24, 2026·$522M
Weave Communications IncWEAV
Special meeting·Oct 22, 2026·$591M
Reference
Frequently asked questions
- When is the Benitec Biopharma Inc 2026 annual meeting?
- Benitec Biopharma Inc (BNTC) holds its 2026 annual shareholder meeting on Thursday, December 3, 2026.
- What is the record date for the Benitec Biopharma Inc 2026 meeting?
- The record date for the Benitec Biopharma Inc 2026 meeting is Tuesday, October 13, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Benitec Biopharma Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Benitec Biopharma Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Benitec Biopharma Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Benitec Biopharma Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.